LEXARIA BIOSCIENCE CORP. Increase Decrease In Operating Lease Liability
LEXARIA BIOSCIENCE CORP. (LEXX) reported Increase Decrease In Operating Lease Liability of -$28.01 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for the quarter ending 2026-05-31 was -$9.34K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for the quarter ending 2026-02-28 was -$9.34K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for the quarter ending 2025-11-30 was -$9.34K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for the quarter ending 2025-08-31 was -$9.34K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for fiscal 2025 was -$37.09K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for fiscal 2024 was -$33.27K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for fiscal 2023 was -$44.81K.
- LEXARIA BIOSCIENCE CORP. increase decrease in operating lease liability for fiscal 2022 was $0.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$9.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | -$18.67K derived: sum of 2 quarters · filed 2026-07-13 | -$28.01K 10-Q · filed 2026-07-13 | -$37.34K derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | -$9.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | -$18.67K 10-Q · filed 2026-04-13 | -$28.01K derived: sum of 3 quarters · filed 2026-04-13 | -$37.34K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | -$9.34K 10-Q · filed 2026-01-13 | -$18.67K derived: sum of 2 quarters · filed 2026-01-13 | -$28.01K derived: sum of 3 quarters · filed 2026-07-13 | -$37.34K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | -$9.34K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | -$18.67K derived: sum of 2 quarters · filed 2026-07-13 | -$28.01K derived: sum of 3 quarters · filed 2026-07-13 | -$37.09K 10-K · filed 2025-11-28 |
| 2025-05-31 | -$9.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | -$18.67K derived: sum of 2 quarters · filed 2026-07-13 | -$27.76K 10-Q · filed 2026-07-13 | -$34.15K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-02-28 | -$9.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | -$18.42K 10-Q · filed 2026-04-13 | -$24.81K derived: sum of 3 quarters · filed 2026-04-13 | -$33.77K derived: sum of 4 quarters · filed 2026-04-13 |
| 2024-11-30 | -$9.09K 10-Q · filed 2026-01-13 | -$15.48K derived: sum of 2 quarters · filed 2026-01-13 | -$24.44K derived: sum of 3 quarters · filed 2026-01-13 | -$33.40K derived: sum of 4 quarters · filed 2026-01-13 |
| 2024-08-31 | -$6.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | -$15.35K derived: sum of 2 quarters · filed 2025-11-28 | -$24.31K derived: sum of 3 quarters · filed 2025-11-28 | -$33.27K 10-K · filed 2025-11-28 |
| 2024-05-31 | -$8.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | -$17.92K derived: sum of 2 quarters · filed 2025-07-14 | -$26.88K 10-Q · filed 2025-07-14 | -$38.09K derived: sum of 4 quarters · filed 2025-07-14 |
| 2024-02-29 | -$8.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | -$17.92K 10-Q · filed 2025-04-14 | -$29.13K derived: sum of 3 quarters · filed 2025-04-14 | -$42.34K derived: sum of 4 quarters · filed 2025-04-14 |
| 2023-11-30 | -$8.96K 10-Q · filed 2025-01-10 | -$20.17K derived: sum of 2 quarters · filed 2025-01-10 | -$33.38K derived: sum of 3 quarters · filed 2025-01-10 | |
| 2023-08-31 | -$11.20K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$24.42K derived: sum of 2 quarters · filed 2024-11-26 | -$44.81K 10-K · filed 2024-11-26 | |
| 2023-05-31 | -$13.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | -$33.61K 10-Q · filed 2024-07-12 | ||
| 2023-02-28 | -$20.40K 10-Q · filed 2024-04-09 | |||
| 2022-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $0.00 derived: sum of 2 quarters · filed 2023-11-20 | $0.00 10-K · filed 2023-11-20 | |
| 2022-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | $0.00 10-Q · filed 2023-07-14 | ||
| 2022-02-28 | $0.00 10-Q · filed 2023-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |